<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-title>The Journal of Experimental Medicine</journal-title><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11034610</article-id><article-id pub-id-type="pmc">2195872</article-id><article-id pub-id-type="publisher-id">000832</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Definitive Report</subject></subj-group></article-categories><title-group><article-title>Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2&#x02013;Nonsteroidal Antiinflammatory Drugs and Transcellular Processing</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Serhan</surname><given-names>Charles N.</given-names></name><address><addr-line>Director, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115.</addr-line><fax>617-278-6957</fax><phone>617-732-8822</phone></address><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Clish</surname><given-names>Clary B.</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Brannon</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Colgan</surname><given-names>Sean P.</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Chiang</surname><given-names>Nan</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><contrib contrib-type="author"><name><surname>Gronert</surname><given-names>Karsten</given-names></name><xref ref-type="aff" rid="a">a</xref></contrib><aff id="a"><label>a</label>Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115</aff></contrib-group><pub-date pub-type="ppub"><day>16</day><month>10</month><year>2000</year></pub-date><volume>192</volume><issue>8</issue><fpage>1197</fpage><lpage>1204</lpage><history><date date-type="received"><day>19</day><month>5</month><year>2000</year></date><date date-type="rev-request"><day>18</day><month>7</month><year>2000</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2000</year></date></history><permissions><copyright-statement>&#x000a9; 2000 The Rockefeller University Press</copyright-statement><copyright-year>2000</copyright-year><copyright-holder>The Rockefeller University Press</copyright-holder></permissions><abstract><p>Aspirin therapy inhibits prostaglandin biosynthesis without directly acting on lipoxygenases, yet via acetylation of cyclooxygenase 2 (COX-2) it leads to bioactive lipoxins (LXs) epimeric at carbon 15 (15-epi-LX, also termed aspirin-triggered LX [ATL]). Here, we report that inflammatory exudates from mice treated with &#x003c9;-3 polyunsaturated fatty acid and aspirin (ASA) generate a novel array of bioactive lipid signals. Human endothelial cells with upregulated COX-2 treated with ASA converted C20:5 &#x003c9;-3 to 18<italic>R</italic>-hydroxyeicosapentaenoic acid (HEPE) and 15<italic>R</italic>-HEPE. Each was used by polymorphonuclear leukocytes to generate separate classes of novel trihydroxy-containing mediators, including 5-series 15<italic>R</italic>-LX<sub>5</sub> and 5,12,18<italic>R</italic>-triHEPE. These new compounds proved to be potent inhibitors of human polymorphonuclear leukocyte transendothelial migration and infiltration in vivo (ATL analogue &#x0003e; 5,12,18<italic>R</italic>-triHEPE &#x0003e; 18<italic>R</italic>-HEPE). Acetaminophen and indomethacin also permitted 18<italic>R</italic>-HEPE and 15<italic>R</italic>-HEPE generation with recombinant COX-2 as well as &#x003c9;-5 and &#x003c9;-9 oxygenations of other fatty acids that act on hematologic cells. These findings establish new transcellular routes for producing arrays of bioactive lipid mediators via COX-2&#x02013;nonsteroidal antiinflammatory drug&#x02013;dependent oxygenations and cell&#x02013;cell interactions that impact microinflammation. The generation of these and related compounds provides a novel mechanism(s) for the therapeutic benefits of &#x003c9;-3 dietary supplementation, which may be important in inflammation, neoplasia, and vascular diseases.</p></abstract><kwd-group><kwd>dietary PUFA</kwd><kwd>eicosanoids</kwd><kwd>leukocytes</kwd><kwd>cardiovascular disease</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Numerous reports of the past 25 years suggest that supplementation of dietary omega-3 polyunsaturated fatty acids (&#x003c9;-3 PUFA) with linseed, canola, or fish oils has beneficial effects in human diseases and laboratory animals (for review see references 1 and 2). These have included lively discussions of potential antithrombotic, immunoregulatory, and antiinflammatory responses relevant in arteriosclerosis, arthritis, and asthma <xref ref-type="bib" rid="R1">1</xref> as well as antitumor and antimetastatic effects <xref ref-type="bib" rid="R3">3</xref>. Their potential for preventative actions in cardiovascular diseases was recently bolstered with the finding that major dietary &#x003c9;-3 PUFAs, eicosapentaenoic acid (C20:5 &#x003c9;-3&#x0003b; EPA) and docosahexaenoic acid (C22:6 &#x003c9;-3&#x0003b; DHA), have a dramatic effect on ischemia-induced ventricular fibrillation and can protect against sudden cardiac death in dogs <xref ref-type="bib" rid="R4">4</xref>. Emergence of such possible preventative and/or therapeutic actions of &#x003c9;-3 PUFA supplementation in infant nutrition, cardiovascular diseases, and mental health has led to a call for recommended dietary intakes by an international workshop <xref ref-type="bib" rid="R5">5</xref>. Also, the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Prevenzione trial evaluated the effects of &#x003c9;-3 PUFA supplementation with &#x0003e;11,300 patients surviving myocardial infarction taking &#x0223c;1 g of &#x003c9;-3 PUFA daily (<italic>n</italic> = 2,836) along with recommended preventive treatments including aspirin, and reported a significant benefit with a decrease in cardiovascular death <xref ref-type="bib" rid="R6">6</xref>. However, the cellular and molecular mechanism(s) for dietary &#x003c9;-3 protective actions in all of the studies to date remain largely unexplained.</p><p>It is believed that the actions of the major lipid of fish oil, C20:5, are based upon (a) preventing conversion of arachidonic acid (C20:4 &#x003c9;-6&#x0003b; AA) to proinflammatory eicosanoids (i.e., prostaglandins [PGs] and leukotrienes [LTs])&#x0003b; (b) serving as an alternate substrate producing 5-series LTs that are less potent&#x0003b; and/or (c) conversion by cyclooxygenase (COX) to 3-series prostanoids (i.e., PGI<sub>3</sub>) with potencies equivalent to their 4-series PG counterparts to maintain antithrombotic actions <xref ref-type="bib" rid="R1">1</xref><xref ref-type="bib" rid="R3">3</xref><xref ref-type="bib" rid="R4">4</xref>. These and other explanations offered <xref ref-type="bib" rid="R1">1</xref><xref ref-type="bib" rid="R2">2</xref><xref ref-type="bib" rid="R3">3</xref><xref ref-type="bib" rid="R4">4</xref><xref ref-type="bib" rid="R5">5</xref> have not been generally accepted because of the lack of molecular evidence in vivo and the high concentrations of &#x003c9;-3 PUFA required to achieve putative &#x0201c;beneficial actions&#x0201d; in vitro.</p><p>Although the proinflammatory roles of LT and PG are well appreciated <xref ref-type="bib" rid="R7">7</xref><xref ref-type="bib" rid="R8">8</xref>, there is new evidence that other eicosanoids derived from arachidonate, namely lipoxins (LXs) and their endogenous analogues, the aspirin-triggered 15 epimer LXs (ATLs), are potent counterregulators of PMN-mediated injury and acute inflammation <xref ref-type="bib" rid="R9">9</xref><xref ref-type="bib" rid="R10">10</xref><xref ref-type="bib" rid="R11">11</xref>. At least two isoforms for COX, the classic site of action for nonsteroidal antiinflammatory drugs (NSAIDs), have been uncovered (COX-1 and 2) that appear to serve separate physiologic and pathophysiologic roles in humans <xref ref-type="bib" rid="R12">12</xref>. Each COX isoform carries dual enzymatic activities, a <italic>bis</italic>oxygenase and a peroxidase. Inhibition of COX-2 is the current focus of several pharmaceutical companies, as selective inhibition of COX&#x02013;2 without blocking COX-1 could reduce unwanted side effects associated with traditional NSAIDs <xref ref-type="bib" rid="R13">13</xref>. In this regard, acetylation of COX-2 by the classic NSAID, aspirin (ASA), prevents the formation of prostanoids <xref ref-type="bib" rid="R12">12</xref>, but the acetylated enzyme remains active in situ to generate 15<italic>R</italic>-hydroxyeicosatetraenoic acid (15<italic>R</italic>-HETE) from C20:4 <xref ref-type="bib" rid="R14">14</xref><xref ref-type="bib" rid="R15">15</xref> that is released and converted by activated inflammatory cells to the 15-epimeric LXs. Synthetic analogues of these natural local mediators with prolonged biological half-life display potent antiinflammatory properties <xref ref-type="bib" rid="R11">11</xref><xref ref-type="bib" rid="R16">16</xref>, providing evidence that cell&#x02013;cell interactions can be responsible for conversion of AA to mediators that possess antiinflammatory properties.</p><p>Oxidation of C20:4 via P450 in endothelial cells (ECs) may also lead to 11,12-epoxyeicosatetraenoic acid that appears to block EC activation <xref ref-type="bib" rid="R17">17</xref>, while nonenzymatic oxidation of EPA can downregulate EC adhesion molecules <xref ref-type="bib" rid="R18">18</xref>. As PMN&#x02013;vessel interactions are pivotal to recruitment and PMN-dependent tissue injury, the local signals involved in their &#x0201c;cross-talk dialogue&#x0201d; are of interest. Our finding that aspirin-acetylated COX-2 remains active in vivo <xref ref-type="bib" rid="R14">14</xref> to generate specific ATLs that can be effectors of well established antiinflammatory reactions offers a mechanism for beneficial effects of ASA that cannot be attributed to inhibition of prostanoids alone <xref ref-type="bib" rid="R8">8</xref><xref ref-type="bib" rid="R12">12</xref>. New therapeutic applications for ASA and related NSAIDs continue to emerge. However, they usually require molecular definition to provide a rationale. This includes the reported prophylactic benefit of ASA in colorectal cancer and the lower risk of a second myocardial infarction (for review see reference <xref ref-type="bib" rid="R19">19</xref>). In view of the qualitatively overlapping beneficial profiles assigned to dietary &#x003c9;-3 PUFA in human disease <xref ref-type="bib" rid="R1">1</xref><xref ref-type="bib" rid="R2">2</xref><xref ref-type="bib" rid="R3">3</xref><xref ref-type="bib" rid="R4">4</xref><xref ref-type="bib" rid="R5">5</xref><xref ref-type="bib" rid="R6">6</xref>, we sought evidence for novel pathways for lipid-derived signals that could possibly provide a molecular basis and also serve as markers for these beneficial actions.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>Zymosan, hematin, NADPH, and ASA were from Sigma-Aldrich. EPA (Cayman Chemical) and other synthetic standards, hydroxy fatty acids, and intermediates used for identification were purchased from Cascade Biochem Ltd. <italic>Bacillus megaterium</italic> was from American Type Culture Collection. Materials used in liquid chromatography tandem mass spectrometry (LC/MS/MS) analyses were from vendors given in reference 20.</p><p>Human PMNs were freshly isolated from venous blood of healthy volunteers (that declined taking medication for 2 wk before donation&#x0003b; Brigham and Women's Hospital protocol no. 88-02642) by Ficoll gradient and enumerated. Human umbilical vein or microvascular ECs (HUVECs or HMVECs, respectively) were cultured for transendothelial migration <xref ref-type="bib" rid="R10">10</xref>. HMVEC monolayers (one, two, or three passages) were seeded (&#x0223c;2 &#x000d7; 10<sup>5</sup> cells/cm<sup>2</sup>) on polycarbonate permeable supports precoated with 0.1% gelatin for incubations with NSAIDs and PUFA.</p><p>Inflammatory exudates were initiated with intrapouch injection of TNF-&#x003b1; (R&#x00026;D Systems) into 6 d dorsal air pouches <xref ref-type="bib" rid="R16">16</xref> with 6&#x02013;8-wk-old male FVB mice (fed standard rodent diet 5001 containing 0.26% n-3 fatty acids) followed by ASA (500 &#x003bc;g) at 3.5 h and 300 &#x003bc;g C20:5/pouch at 4 h. At 6 h, pouches were lavaged (3 ml saline), and exudate cells were enumerated and activated (4 &#x003bc;M A<sub>23187</sub>, 37&#x000b0;C, 20 min). Inhibition of TNF-&#x003b1;&#x02013;stimulated (100 ng/pouch, FVB strain) PMN infiltration with intravenous tail injection of either 18<italic>R</italic>-hydroxyeicosapentaenoic acid (HEPE), 5,12,18<italic>R</italic>-HEPE, or 15-epi-LXA<sub>4</sub> analogue was determined <xref ref-type="bib" rid="R16">16</xref> with pouch lavages taken at 4 h.</p><p>Specific [<sup>3</sup>H]LTB<sub>4</sub> (NEN Life Science Products) binding was performed with human embryonic kidney (HEK)293 cells stably transfected with human LTB<sub>4</sub> receptor <xref ref-type="bib" rid="R11">11</xref>. Human recombinant COX-2 (a gift from Dr. R.A. Copeland, DuPont Merck, Wilmington, DE) was overexpressed in <italic>Sf</italic>9 insect cells (American Type Culture Collection) with microsomal fractions (&#x0223c;8 &#x003bc;l) suspended in Tris (100 mM, pH 8.0) as in reference <xref ref-type="bib" rid="R21">21</xref>. NSAIDs were incubated (i.e., ASA, &#x0223c;1 mM) at 37&#x000b0;C for 30 min before addition of PUFA (20 &#x003bc;M), and conversions were also monitored using 1-<sup>14</sup>C&#x02013;labeled C20:4 or C20:5 (NEN Life Science Products). <italic>B</italic>. <italic>megaterium</italic> was grown in Bacto Nutrient Broth (Fisher Scientific) at 30&#x000b0;C with shaking. To prepare standards for 18<italic>R</italic>-HEPE, a biogenic synthesis was used with <italic>B</italic>. <italic>megaterium</italic> sonicates incubated with NADPH (2 mM) and C20:5 (330 &#x003bc;M) in 2 M Tris buffer, pH 8.1. Similar conditions were employed to convert LTB<sub>5</sub> (15 &#x003bc;M) to novel products&#x0003b; see Results. Incubations were extracted <xref ref-type="bib" rid="R9">9</xref> with deuterium-labeled internal standards (15-HETE and C20:4) for LC/MS/MS analysis <xref ref-type="bib" rid="R14">14</xref><xref ref-type="bib" rid="R16">16</xref> using a Finnigan LCQ equipped with a LUNA C18-2 (150 &#x000d7; 2 mm&#x0003b; 5 &#x003bc;M) column and a rapid spectra scanning UV/Vis detector. Also, a Chiralcel OB-H column (J.T. Baker) was used to determine <italic>R</italic> and <italic>S</italic> alcohol configurations of monohydroxy-PUFA using isocratic (hexane/isopropanol 96:4 vol/vol). Detailed procedures for isolation, quantitation, and structural determination of lipid-derived mediators were recently reported <xref ref-type="bib" rid="R20">20</xref> and used here essentially as described for the elucidation of the novel products.</p></sec><sec><title>Results and Discussion</title><p>Because ASA triggers formation of epimeric forms of naturally occurring bioactive eicosanoids <xref ref-type="bib" rid="R9">9</xref>, we tested the concept that NSAIDs might promote the formation of novel mediators from &#x003c9;-3 PUFAs. Inflammatory exudates formed in murine air pouches via intrapouch injections of TNF-&#x003b1; with &#x003c9;-3 and ASA on board (2 h) generated several novel compounds (<xref ref-type="fig" rid="F1">Fig. 1</xref>). These mice were fed a standard rodent diet containing 0.26% &#x003c9;-3 PUFA. LC/MS/MS analyses of the exudate-derived materials demonstrated monohydroxy acids, depicted in selected ion chromatograms from acquired results recalled at m/z 317 (<xref ref-type="fig" rid="F1">Fig. 1</xref> A), i.e., 18-hydroxy-EPA (18-HEPE) and 5-HEPE, which coeluted with synthetic 5<italic>S</italic>-HEPE as well as novel trihydroxy-containing compounds derived from C20:5. LC retention times and MS/MS spectra (<xref ref-type="fig" rid="F1">Fig. 1B</xref> and <xref ref-type="fig" rid="F1">Fig. C</xref>) gave product ions consistent with structures shown in the respective insets, namely m/z 317 = [M-H]<sup>&#x02212;</sup>, 299 = [M-H]<sup>&#x02212;</sup>&#x02013;H<sub>2</sub>O, 273 = [M-H]<sup>&#x02212;</sup>&#x02013;CO<sub>2</sub>, 255 = [M-H]<sup>&#x02212;</sup>&#x02013;H<sub>2</sub>O,&#x02013;CO<sub>2</sub>. Diagnostic ions consistent with 18-HEPE identification were present at m/z 259 (<xref ref-type="fig" rid="F1">Fig. 1</xref> B) and 5-HEPE at m/z 115 (<xref ref-type="fig" rid="F1">Fig. 1</xref> C). These criteria were used throughout for identification. The stereochemistry of the alcohol at carbon 18 was established for exudate-derived 18-HEPE using a chiral column, and a reference 18<italic>R</italic>-HEPE was prepared via biogenic synthesis using <italic>B</italic>. <italic>megaterium</italic> (see Materials and Methods). This microbe monooxygenates fatty acids and, for example, converts C20:4 to 18<italic>R</italic>-HETE <xref ref-type="bib" rid="R22">22</xref><xref ref-type="bib" rid="R23">23</xref>. The alcohol configuration at position 18 proved to be &#x0003e;98% <italic>R</italic>. These findings indicated that murine inflammatory exudates exposed in vivo to C20:5, &#x003c9;-3 and ASA produced 5-lipoxygenase pathway 5-series 5<italic>S</italic>-HEPE, a product also identified with human PMNs <xref ref-type="bib" rid="R24">24</xref>, as well as a novel 18<italic>R</italic>-HEPE, whose route of formation was determined (vide infra). Air pouch inflammatory exudate cells from these ASA- and EPA-treated mice contained predominantly PMN (as in <xref ref-type="fig" rid="F1">Fig. 1</xref>), which were 25&#x02013;60% lower in number than in exudates formed with TNF-&#x003b1; alone (<italic>n</italic> = 3). Also, these exudates, when activated with ionophore A<sub>23187</sub> (4 &#x003bc;M), generated essentially equivalent amounts of 18<italic>R</italic>-HEPE (10.2 &#x000b1; 4.3 ng/10<sup>6</sup> cells) and 5<italic>S</italic>-HEPE (10.9 &#x000b1; 2.9 ng/10<sup>6</sup> cells).</p><p>Evidence for novel trihydroxy-containing products was also obtained in these inflammatory exudates (<xref ref-type="fig" rid="F1">Fig. 1</xref> D). Ions present within MS/MS were consistent with a trihydroxy-containing product from C20:5 with a parent ion at m/z 349 = [M-H]<sup>&#x02212;</sup> and product ions of structural significance present at m/z 291 and 195 that are consistent with fragmentations denoted in the inset (<xref ref-type="fig" rid="F1">Fig. 1</xref> D). Also, an observed 270 nm UV absorbance maximum, indicative of a conjugated triene, together with the presence of the m/z = 291 (cleavage C17&#x02013;C18 positions) as well as the 20-carbon structure, implicated that 18<italic>R</italic>-HEPE and the triHEPE were biosynthetically related.</p><p>It was of interest to determine whether these new compounds were also generated by human cells and if they possess bioactivities. To this end, human ECs known to induce COX-2 with IL-1&#x003b2; <xref ref-type="bib" rid="R9">9</xref> or hypoxia (not shown) were pulsed with EPA and treated with ASA, and extracted materials were subject to LC/MS/MS analysis (<xref ref-type="fig" rid="F2">Fig. 2</xref> A). Selected ion monitoring at m/z 259 revealed that HUVECs treated with ASA converted EPA to 18<italic>R</italic>-HEPE (<xref ref-type="fig" rid="F2">Fig. 2</xref> A). Also, HMVECs treated with ASA and EPA generated 18-HEPE (10.6 ng/10<sup>6</sup> cells) and 15-HEPE (6.0 ng/10<sup>6</sup> cells) (<italic>n</italic> = 2, four determinations&#x0003b; data not shown). These observations implicated the involvement of COX-2 in the generation of these compounds, which proved to be the case with recombinant human COX-2 exposure to ASA and &#x003c9;-3 PUFA (<xref ref-type="table" rid="T1">Table </xref>), findings that may be of clinical significance.</p><p>As shown in <xref ref-type="table" rid="T1">Table </xref>, linoleic acid (C18:2) was converted to both 13-hydroxy-9Z,11E-octadecadienoic acid (13-HODE&#x0003b; &#x003c9;-5 oxygenation) and 9-HODE (&#x003c9;-9), which were greatly diminished by ASA but not completely abolished. AA was converted to 15<italic>R</italic>-HETE (&#x003c9;-5) as well as 11<italic>R</italic>-HETE (&#x003c9;-9), consistent with earlier findings <xref ref-type="bib" rid="R9">9</xref>. ASA triggered the appearance of a lipoxygenase activity that switched to 15<italic>R</italic>-HETE production by acetylated COX-2 <xref ref-type="bib" rid="R9">9</xref><xref ref-type="bib" rid="R14">14</xref><xref ref-type="bib" rid="R15">15</xref>, which did not appear to influence 11<italic>R</italic>-HETE formation (<xref ref-type="table" rid="T1">Table </xref>). 11<italic>R</italic>-HEPE was the major product with EPA and COX-2, with lesser amounts of 15<italic>R</italic>-HEPE (&#x003c9;-5) and 18<italic>R</italic>-HEPE (&#x003c9;-2). 1-<sup>14</sup>C&#x02013;labeled EPA was used to confirm precursor&#x02013;product relationships (<italic>n</italic> = 3). ASA acetylation of COX-2 led to an approximately twofold increase in 18<italic>R</italic>-HEPE (&#x003c9;-2), with a &#x0003e;85% reduction in 11<italic>R</italic>-HEPE (the ratio of positional oxygenations with C20:5 was 1:1:0.3, with 18<italic>R</italic> &#x02248; 15<italic>R</italic> &#x0003e; 11<italic>R</italic>). Hence, together they suggested that acetylated COX-2 in ECs (<xref ref-type="fig" rid="F2">Fig. 2</xref>) was a dominant source of 18<italic>R</italic>-HEPE and 15<italic>R</italic>-HEPE.</p><p>Interestingly and unlike the isolated COX-2 product profiles, neither 11<italic>R</italic>-HEPE (from C20:5) nor 11<italic>R</italic>-HETE (from C20:4) were major products of the vascular ECs (<xref ref-type="table" rid="T1">Table </xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>). With the selective COX-2 inhibitor NS398 <xref ref-type="bib" rid="R12">12</xref><xref ref-type="bib" rid="R13">13</xref>, these oxygenations were reduced, and only 18<italic>R</italic>-HEPE formation from EPA appeared to escape inhibition (<xref ref-type="table" rid="T1">Table </xref>). These results suggest that ASA treatment at local sites of inflammation along with &#x003c9;-3 PUFA (i.e., EPA&#x0003b; C20:5, &#x003c9;-3) administration, as exemplified by cytokine-driven acute inflammation (<xref ref-type="fig" rid="F1">Fig. 1</xref>), can convert EPA via COX-2 to 18<italic>R</italic>-HEPE and 15<italic>R</italic>-HEPE.</p><p>Because human PMNs convert ASA-triggered, COX-2&#x02013;derived 15<italic>R</italic>-HETE to 15-epi-LXA<sub>4</sub> <xref ref-type="bib" rid="R9">9</xref> and EPA is converted to 5-series LX by human leukocytes <xref ref-type="bib" rid="R25">25</xref> as well as trout macrophages <xref ref-type="bib" rid="R26">26</xref>, we next evaluated whether activated human PMNs engaged in phagocytosis handle acetylated COX-2&#x02013;derived C20:5, &#x003c9;-3 products 18<italic>R</italic>-HEPE and 15<italic>R</italic>-HEPE. Serum-treated zymosan, a phagocytic stimulus, initiated the utilization and conversion of acetylated COX-2 C20:5-derived products to two classes of trihydroxy-containing EPE, determined again by selected ion monitoring at m/z 349.5 [M-H]<sup>&#x02212;</sup>, the base peak molecular ion for these products (<xref ref-type="fig" rid="F2">Fig. 2</xref> B). One, shown in <xref ref-type="fig" rid="F2">Fig. 2</xref> C, gave essentially the same MS/MS observed in <xref ref-type="fig" rid="F1">Fig. 1</xref> D from murine cells and was consistent with the 5,12,18<italic>R</italic>-triHEPE structure depicted in the inset giving diagnostic ions (<xref ref-type="fig" rid="F2">Fig. 2</xref> C) at m/z 305, 233, 195, and 291 (<xref ref-type="fig" rid="F1">Fig. 1</xref> D). This product is an 18<italic>R</italic>-hydroxy&#x02013;carrying &#x0201c;LTB<sub>5</sub>-like&#x0201d; structure (see <xref ref-type="fig" rid="F2">Fig. 2</xref> D, inset). Indeed, when isolated 18<italic>R</italic>-HEPE was incubated as above with activated PMNs, it was converted to several compounds, including this product. Also, synthetic LTB<sub>5</sub> incubated with <italic>B</italic>. <italic>megaterium</italic> homogenates and NADPH at pH 8.0 to facilitate hydroxylations <xref ref-type="bib" rid="R23">23</xref> was transformed to a trihydroxy product (<italic>n</italic> = 3) with an m/z 291 ion characteristic for the presence of the 18<italic>R</italic> alcohol group as obtained from human PMNs shown in <xref ref-type="fig" rid="F2">Fig. 2</xref> C. These independent lines of evidence indicated that PMNs take up 18<italic>R</italic>-HEPE, which is converted by their 5-lipoxygenase, to insert molecular oxygen and in subsequent steps to 5-hydro(peroxy)-18<italic>R</italic>-DiH(p)EPE and 5(6)epoxide formation to 5,12,18<italic>R</italic>-triHEPE (an 18<italic>R</italic>-carrying LTB<sub>5</sub>-like product) that is likely to possess the stereochemistry of LTB<sub>5</sub> <xref ref-type="bib" rid="R24">24</xref>, retaining the 18<italic>R</italic> chirality of the precursor.</p><p>In an analogous biosynthetic fashion, 15<italic>R</italic>-HEPE was converted by PMN via 5-lipoxygenation to a 5-series LXA<sub>5</sub> analogue (<xref ref-type="fig" rid="F2">Fig. 2</xref> D) that also retains their C15 configuration. Its MS/MS gave prominent ions, m/z 305, 233, and 251, depicted in the MS/MS spectrum, namely 15-epi-LXA<sub>5</sub>, consistent with 15<italic>S</italic>-containing LX<sub>5</sub> structures (5-series) observed from endogenous sources of EPA in trout macrophages <xref ref-type="bib" rid="R26">26</xref>. In this case, the chirality of the precursor 15<italic>R</italic> is retained by human PMN to give 15-epi-LXA<sub>5</sub> (<xref ref-type="fig" rid="F2">Fig. 2</xref> D), which is the 5-series &#x003c9;-3 analogue of 15-epi-LXA<sub>4</sub>. As with LX biosynthesis, conversion of both 18<italic>R</italic>- and 15<italic>R</italic>-HEPE by activated PMNs with 5-lipoxygenation was accompanied with a reduction in LTB<sub>4</sub> formation (not shown). Together, these results indicate that isolated human ECs and PMNs (<xref ref-type="fig" rid="F2">Fig. 2</xref>) can generate the novel products observed with inflammatory exudates (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><p>Transendothelial migration is a pivotal event in PMN recruitment and inflammation and a recognized locus of action for traditional antiinflammatory therapies <xref ref-type="bib" rid="R27">27</xref>. Endogenous lipid mediators that can control these cell&#x02013;cell interactions are of interest. Therefore, we isolated and assessed 5,12,18<italic>R</italic>-triHEPE and its precursor 18<italic>R</italic>-HEPE on human PMN transmigration. Both compounds inhibited LTB<sub>4</sub>-stimulated PMN transendothelial migration (<xref ref-type="fig" rid="F3">Fig. 3</xref> A) with an apparent IC<sub>50</sub> of 5&#x02013;50 nM for 5,12,18<italic>R</italic>-triHEPE and IC<sub>50</sub> &#x0003e;1.0 &#x003bc;M for 18<italic>R</italic>-HEPE. Thus, the new 5-series members, namely, 18<italic>R</italic>-carrying trihydroxy-HEPE and 18<italic>R</italic>-HEPE, inhibited PMN migration, as did 15-epi-LXA<sub>4</sub> and its omega end analogue <xref ref-type="bib" rid="R10">10</xref><xref ref-type="bib" rid="R16">16</xref>, tested in parallel for direct comparison (<xref ref-type="fig" rid="F3">Fig. 3</xref> A). Their rank order of potency was 15-epi-LXA<sub>4</sub> stable analogue &#x0003e; 5,12,18<italic>R</italic>-triHEPE &#x0003e; 18<italic>R</italic>-HEPE.</p><p>The G protein&#x02013;coupled receptor for LTB<sub>4</sub> was identified <xref ref-type="bib" rid="R28">28</xref>, and to determine whether these 18<italic>R</italic>-containing products interact with the human LTB<sub>4</sub> receptors to block PMNs, this receptor was cloned <xref ref-type="bib" rid="R11">11</xref> from reported sequences <xref ref-type="bib" rid="R28">28</xref> and stably expressed in HEK293 cells for competition binding experiments (<xref ref-type="fig" rid="F3">Fig. 3</xref> B). The homoligand LTB<sub>4</sub> effectively competed (IC<sub>50</sub> &#x02248; 2.5 nM). 18<italic>R</italic>-HEPE did not, while both LTB<sub>5</sub> and 5,12,18<italic>R</italic>-triHEPE competed (IC<sub>50</sub> &#x0223c;0.5 &#x003bc;M), giving a trend with LTB<sub>5</sub> &#x0003e; 5,12,18<italic>R</italic>-triHEPE. Although the 5,12,18<italic>R</italic>-triHEPE and a related structure (i.e., LTB<sub>5</sub>) were substantially less effective than 4-series LTB<sub>4</sub>, consistent with the reduced PMN activity of LTB<sub>5</sub> <xref ref-type="bib" rid="R24">24</xref>, their potency for displacing [<sup>3</sup>H]LTB<sub>4</sub> was in the range of currently available synthetic LTB<sub>4</sub> receptor antagonists (not shown). These findings suggest that 5,12,18<italic>R</italic>-triHEPE might serve as a damper for LT-mediated responses in vivo if generated in appropriate quantities within the microenvironment as well as a biotemplate for total synthesis of new classes of receptor antagonists. When administered intravenously into tail at low levels (100 ng), 5,12,18<italic>R</italic>-triHEPE was a potent inhibitor of PMN infiltration into murine dorsal air pouches (<xref ref-type="fig" rid="F3">Fig. 3</xref> C), as was a 15-epi-LX stable analogue <xref ref-type="bib" rid="R16">16</xref> given at equivalent doses for the purpose of direct comparison. 18<italic>R</italic>-HEPE also carried some activity in vivo (&#x0003c;5,12,18<italic>R</italic>-triHEPE), whereas it was far less effective with isolated human PMNs in transendothelial migration and apparently did not interact with recombinant LTB<sub>4</sub> receptors at these concentrations.</p><p>Other widely used NSAIDs (i.e., acetaminophen and indomethacin) were also tested with recombinant COX-2 and C20:5 as in <xref ref-type="table" rid="T1">Table </xref> to determine whether they altered conversion to HEPE. Each inhibited 11-HEPE by &#x0003e;95%. Interestingly, 18<italic>R</italic>-HEPE and 15<italic>R</italic>-HEPE formation persisted (&#x0223c;1:1 ratio) in the presence of either acetaminophen or indomethacin at concentrations as high as 2 mM, even though the levels of 15<italic>R</italic>- and 18<italic>R</italic>-HEPE were reduced by three to eight times their levels in the absence of inhibitors (<italic>n</italic> = 3). These findings indicate that the oxygenation of &#x003c9;-3 fatty acids to <italic>R</italic>-containing monohydro(peroxy)-containing products is not restricted to ASA treatment and arachidonate. Hence, these commonly used NSAIDs and selective COX-2 inhibitors (<xref ref-type="table" rid="T1">Table </xref>) may still permit PUFA oxygenation by activated ECs exposed to NSAIDs (<xref ref-type="fig" rid="F2">Fig. 2</xref>) and at sites of inflammation where the degree of COX-2 interactions with drugs may be &#x0201c;leaky,&#x0201d; permitting novel oxygenation of PUFAs.</p><p>Despite the many reports of &#x003c9;-3 PUFAs (i.e., C20:5) possible beneficial impact in humans <xref ref-type="bib" rid="R1">1</xref><xref ref-type="bib" rid="R2">2</xref><xref ref-type="bib" rid="R3">3</xref><xref ref-type="bib" rid="R4">4</xref><xref ref-type="bib" rid="R5">5</xref><xref ref-type="bib" rid="R6">6</xref>, oxygenation by COX-2 to generate novel bioactive compounds has not been addressed in humans or isolated cells. In fish, both C20:5 and C20:4 are mobilized in macrophages and platelets to produce 5- and 4-series eicosanoids, including PG, LT, and LX, with essentially equal abundance <xref ref-type="bib" rid="R26">26</xref>. Our results indicate that inflammatory exudates from mice treated with ASA and EPA generate novel compounds (<xref ref-type="fig" rid="F1">Fig. 1</xref>) that are also produced by human ECs, recombinant COX-2, and PMNs (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Given the milligram to gram amounts of &#x003c9;-3 PUFA taken as dietary supplements <xref ref-type="bib" rid="R1">1</xref><xref ref-type="bib" rid="R2">2</xref><xref ref-type="bib" rid="R3">3</xref><xref ref-type="bib" rid="R4">4</xref><xref ref-type="bib" rid="R5">5</xref><xref ref-type="bib" rid="R6">6</xref> and the large area of microvasculature that can carry upregulated COX-2, the conversion of EPA by ECs and neighboring cells as observed in our experiments (<xref ref-type="fig" rid="F1">Fig. 1</xref><xref ref-type="fig" rid="F2">Fig. 2</xref><xref ref-type="fig" rid="F3">Fig. 3</xref><xref ref-type="fig" rid="F4">Fig. 4</xref>) may represent a significant amount at local microenvironments. These COX-2&#x02013;NSAID-dependent conversions of &#x003c9;-3 PUFA are likely to be elevated within inflamed or diseased tissues where COX-2 is upregulated and a determinant that impacts fatty acid metabolism <xref ref-type="bib" rid="R14">14</xref> when NSAIDs might be of therapeutic benefit, namely with microinflammation.</p><p>Analogous to 15-epi-LX biosynthesis, EPA COX-2&#x02013;derived 15<italic>R</italic>-HEPE was converted by 5-lipoxygenation with 5(6)-epoxide formation in leukocytes to give the 15-epi-LX<sub>5</sub> series (<xref ref-type="fig" rid="F4">Fig. 4</xref>). The stable analogues of 15-epi-LXA<sub>4</sub>, modified at their C15 position through position 20 with bulky groups, resist inactivating enzymes and are more potent in vivo, inhibiting PMN traffic as well as formation and actions of key proinflammatory cytokines <xref ref-type="bib" rid="R10">10</xref><xref ref-type="bib" rid="R16">16</xref>. Hence, 5-series 15-epi-LXs should act in a similar fashion, as they possess a &#x00394;17&#x02013;18 double bond and thus could function as an &#x003c9;-3&#x02013;derived 15-epi-LX analogue.</p><p>Because COX-2&#x02013;NSAID-dependent oxygenation (e.g., 18<italic>R</italic> and15<italic>R</italic>) led to bioactive compounds in vivo that block PMN transendothelial migration and infiltration, our findings provide a basis for a novel mechanism of action of NSAIDs and dietary &#x003c9;-3 supplementation, namely the generation of endogenous functional arrays of lipid signals (<xref ref-type="table" rid="T1">Table </xref> and <xref ref-type="fig" rid="F1">Fig. 1</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>) that could, by dampening key events in microinflammation, mediate some of the beneficial actions noted for &#x003c9;-3 therapies in human trials <xref ref-type="bib" rid="R1">1</xref><xref ref-type="bib" rid="R2">2</xref><xref ref-type="bib" rid="R3">3</xref><xref ref-type="bib" rid="R4">4</xref><xref ref-type="bib" rid="R5">5</xref><xref ref-type="bib" rid="R6">6</xref>. In this context, 13-HODE, a recognized lipoxygenase product that downregulates platelet&#x02013;EC interactions <xref ref-type="bib" rid="R29">29</xref>, is also generated by COX-2 (<xref ref-type="table" rid="T1">Table </xref>) and joins this pathway array and class of mediators. As inappropriate inflammatory responses are now recognized as contributors to cardiovascular disease <xref ref-type="bib" rid="R30">30</xref> as well as in clinical syndromes where PMN-mediated tissue injury is important <xref ref-type="bib" rid="R11">11</xref>, our identification of these novel &#x003c9;-3 PUFA processing pathways evoked by cell&#x02013;cell interactions and the unexpected impact of NSAIDs opens new avenues for considering the potential clinical protection provided by &#x003c9;-3 PUFA&#x02013;based supplementation (as from reference 6) and mechanisms to generate potent local endogenous mediators that control microinflammation (<xref ref-type="fig" rid="F3">Fig. 3</xref> and <xref ref-type="fig" rid="F4">Fig. 4</xref>). Moreover, our findings offer a basis to circumvent unwanted effects of current antiinflammatory therapies as well as potential biochemical indices and/or markers of effective dietary &#x003c9;-3 supplementation.</p></sec></body><back><ack><p>We thank Mary Halm Small for assistance in manuscript preparation and Rachel Cochran for technical assistance.</p><p>This work was supported in part by National Institutes of Health grants GM38765 (to C.N. Serhan), HL60569 (to S.P. Colgan), and P01-DE13499 (to C.N. Serhan). C. Clish is the McDuffie Postdoctoral Fellow of the Arthritis Foundation, and K. Gronert is a recipient of a National Research Service Award (F32-AI10389).</p></ack><ref-list><ref id="R1"><citation citation-type="book"><person-group person-group-type="editor"><name><surname>De Caterina</surname><given-names>R.</given-names></name><name><surname>Endres</surname><given-names>S.</given-names></name><name><surname>Kristensen</surname><given-names>S.D.</given-names></name><name><surname>Schmidt</surname><given-names>E.B.</given-names></name></person-group><source>n-3 Fatty Acids and Vascular Disease</source><year>1993</year><publisher-name>Springer-Verlag</publisher-name><publisher-loc>London</publisher-loc>pp. 166 </citation></ref><ref id="R2"><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Lands</surname><given-names>W.E.M.</given-names></name></person-group><source>Proc. AOCS Short Course on Polyunsaturated Fatty Acids and Eicosanoids</source><year>1987</year><publisher-name>American Oil Chemists' Society</publisher-name><publisher-loc>Champaign, IL</publisher-loc>pp. 574</citation></ref><ref id="R3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iigo</surname><given-names>M.</given-names></name><name><surname>Nakagawa</surname><given-names>T.</given-names></name><name><surname>Ishikawa</surname><given-names>C.</given-names></name><name><surname>Iwahori</surname><given-names>Y.</given-names></name><name><surname>Asamoto</surname><given-names>M.</given-names></name><name><surname>Yazawa</surname><given-names>K.</given-names></name><name><surname>Araki</surname><given-names>E.</given-names></name><name><surname>Tsuda</surname><given-names>H.</given-names></name></person-group><article-title>Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung</article-title><source>Br. J. Cancer.</source><volume>75</volume><year>1997</year><fpage>650</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">9043019</pub-id></citation></ref><ref id="R4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Billman</surname><given-names>G.E.</given-names></name><name><surname>Kang</surname><given-names>J.X.</given-names></name><name><surname>Leaf</surname><given-names>A.</given-names></name></person-group><article-title>Prevention of sudden cardiac death by dietary pure &#x003c9;-3 polyunsaturated fatty acids in dogs</article-title><source>Circulation.</source><volume>99</volume><year>1999</year><fpage>2452</fpage><lpage>2457</lpage><pub-id pub-id-type="pmid">10318669</pub-id></citation></ref><ref id="R5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simopoulos</surname><given-names>A.P.</given-names></name><name><surname>Leaf</surname><given-names>A.</given-names></name><name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids</article-title><source>J. Am. Coll. Nutr.</source><volume>18</volume><year>1999</year><fpage>487</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">10511332</pub-id></citation></ref><ref id="R6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchioli</surname><given-names>R.</given-names></name></person-group><article-title>Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarctionresults of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico</article-title><source>Lancet.</source><volume>354</volume><year>1999</year><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">10465168</pub-id></citation></ref><ref id="R7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weissmann</surname><given-names>G.</given-names></name></person-group><article-title>Aspirin</article-title><source>Sci. Am.</source><volume>264</volume><year>1991</year><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">1899486</pub-id></citation></ref><ref id="R8"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>A.J.</given-names></name></person-group><article-title>Plateletstheir role in hemostasis, thrombosis, and inflammation</article-title><person-group person-group-type="editor"><name><surname>Gallin</surname><given-names>J.I.</given-names></name><name><surname>Snyderman</surname><given-names>R.</given-names></name></person-group><source>InflammationBasic Principles and Clinical Correlates</source><year>1999</year><fpage>77</fpage><lpage>95</lpage><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Philadelphia</publisher-loc></citation></ref><ref id="R9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cl&#x000e0;ria</surname><given-names>J.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions</article-title><source>Proc. Natl. Acad. Sci. USA.</source><volume>92</volume><year>1995</year><fpage>9475</fpage><lpage>9479</lpage><pub-id pub-id-type="pmid">7568157</pub-id></citation></ref><ref id="R10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Maddox</surname><given-names>J.F.</given-names></name><name><surname>Petasis</surname><given-names>N.A.</given-names></name><name><surname>Akritopoulou-Zanze</surname><given-names>I.</given-names></name><name><surname>Papayianni</surname><given-names>A.</given-names></name><name><surname>Brady</surname><given-names>H.R.</given-names></name><name><surname>Colgan</surname><given-names>S.P.</given-names></name><name><surname>Madara</surname><given-names>J.L.</given-names></name></person-group><article-title>Design of lipoxin A<sub>4</sub> stable analogs that block transmigration and adhesion of human neutrophils</article-title><source>Biochemistry.</source><volume>34</volume><year>1995</year><fpage>14609</fpage><lpage>14615</lpage><pub-id pub-id-type="pmid">7578068</pub-id></citation></ref><ref id="R11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Clish</surname><given-names>C.B.</given-names></name><name><surname>O'Brien</surname><given-names>J.A.</given-names></name><name><surname>Freeman</surname><given-names>M.W.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Leukotriene B<sub>4</sub> receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion</article-title><source>J. Clin. Invest.</source><volume>104</volume><year>1999</year><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">10430612</pub-id></citation></ref><ref id="R12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herschman</surname><given-names>H.R.</given-names></name></person-group><article-title>Recent progress in the cellular and molecular biology of prostaglandin synthesis</article-title><source>Trends Cardiovasc. Med.</source><volume>8</volume><year>1998</year><fpage>145</fpage><lpage>150</lpage></citation></ref><ref id="R13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Needleman</surname><given-names>P.</given-names></name><name><surname>Isakson</surname><given-names>P.C.</given-names></name></person-group><article-title>The discovery and function of COX-2</article-title><source>J. Rheumatol.</source><volume>24</volume>Suppl. 49<year>1997</year><fpage>6</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9002003</pub-id></citation></ref><ref id="R14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Takano</surname><given-names>T.</given-names></name><name><surname>Clish</surname><given-names>C.B.</given-names></name><name><surname>Petasis</surname><given-names>N.A.</given-names></name><name><surname>Tai</surname><given-names>H.-H.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Aspirin-triggered 15-epi-lipoxin A<sub>4</sub> (ATL) generation by human leukocytes and murine peritonitis exudatesdevelopment of a specific 15-epi-LXA<sub>4</sub> ELISA</article-title><source>J. Pharmacol. Exp. Ther.</source><volume>287</volume><year>1998</year><fpage>779</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">9808710</pub-id></citation></ref><ref id="R15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>G.</given-names></name><name><surname>Tsai</surname><given-names>A.-L.</given-names></name><name><surname>Palmer</surname><given-names>G.</given-names></name><name><surname>Boyar</surname><given-names>W.C.</given-names></name><name><surname>Marshall</surname><given-names>P.J.</given-names></name><name><surname>Kulmacz</surname><given-names>R.J.</given-names></name></person-group><article-title>Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2</article-title><source>Biochemistry.</source><volume>36</volume><year>1997</year><fpage>1836</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">9048568</pub-id></citation></ref><ref id="R16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clish</surname><given-names>C.B.</given-names></name><name><surname>O'Brien</surname><given-names>J.A.</given-names></name><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Stahl</surname><given-names>G.L.</given-names></name><name><surname>Petasis</surname><given-names>N.A.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo</article-title><source>Proc. Natl. Acad. Sci. USA.</source><volume>96</volume><year>1999</year><fpage>8247</fpage><lpage>8252</lpage><pub-id pub-id-type="pmid">10393980</pub-id></citation></ref><ref id="R17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Node</surname><given-names>K.</given-names></name><name><surname>Huo</surname><given-names>Y.</given-names></name><name><surname>Ruan</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Spiecker</surname><given-names>M.</given-names></name><name><surname>Ley</surname><given-names>K.</given-names></name><name><surname>Zeldin</surname><given-names>D.C.</given-names></name><name><surname>Liao</surname><given-names>J.K.</given-names></name></person-group><article-title>Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids</article-title><source>Science.</source><volume>285</volume><year>1999</year><fpage>1276</fpage><lpage>1279</lpage><pub-id pub-id-type="pmid">10455056</pub-id></citation></ref><ref id="R18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>S.</given-names></name><name><surname>Eastman</surname><given-names>A.Y.</given-names></name><name><surname>Eaton</surname><given-names>J.W.</given-names></name></person-group><article-title>Inhibition of phagocyte-endothelium interactions by oxidized fatty acidsa natural anti-inflammatory mechanism?</article-title><source>J. Lab. Clin. Med.</source><volume>128</volume><year>1996</year><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">8759934</pub-id></citation></ref><ref id="R19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>G.N.</given-names></name></person-group><article-title>Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer</article-title><source>FASEB J.</source><volume>11</volume><year>1997</year><fpage>234</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">9068612</pub-id></citation></ref><ref id="R20"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gronert</surname><given-names>K.</given-names></name><name><surname>Clish</surname><given-names>C.B.</given-names></name><name><surname>Romano</surname><given-names>M.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Transcellular regulation of eicosanoid biosynthesis</article-title><person-group person-group-type="editor"><name><surname>Lianos</surname><given-names>E.A.</given-names></name></person-group><source>Eicosanoid Protocols</source><year>1999</year><fpage>119</fpage><lpage>144</lpage><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ</publisher-loc></citation></ref><ref id="R21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>H.J.</given-names></name><name><surname>Van Dyk</surname><given-names>D.E.</given-names></name><name><surname>Straney</surname><given-names>R.A.</given-names></name><name><surname>Trzaskos</surname><given-names>J.M.</given-names></name><name><surname>Copeland</surname><given-names>R.A.</given-names></name></person-group><article-title>Expression purification and characterization of recombinant human inducible prostaglandin G/H synthase from baculovirus-infected insect cells</article-title><source>Protein Expr. Purif.</source><volume>7</volume><year>1996</year><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9172778</pub-id></citation></ref><ref id="R22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Capdevila</surname><given-names>J.H.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Helvig</surname><given-names>C.</given-names></name><name><surname>Falck</surname><given-names>J.R.</given-names></name><name><surname>Belosludtsev</surname><given-names>Y.</given-names></name><name><surname>Truan</surname><given-names>G.</given-names></name><name><surname>Graham-Lorence</surname><given-names>S.E.</given-names></name><name><surname>Peterson</surname><given-names>J.A.</given-names></name></person-group><article-title>The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3</article-title><source>J. Biol. Chem.</source><volume>271</volume><year>1996</year><fpage>22663</fpage><lpage>22671</lpage><pub-id pub-id-type="pmid">8798438</pub-id></citation></ref><ref id="R23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruettinger</surname><given-names>R.T.</given-names></name><name><surname>Fulco</surname><given-names>A.J.</given-names></name></person-group><article-title>Epoxidation of unsaturated fatty acids by a soluble cytochrome P-450-dependent system from <italic>Bacillus megaterium</italic></article-title><source>J. Biol. Chem.</source><volume>256</volume><year>1981</year><fpage>5728</fpage><lpage>5734</lpage><pub-id pub-id-type="pmid">6787044</pub-id></citation></ref><ref id="R24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.H.</given-names></name><name><surname>Menica-Huerta</surname><given-names>J.M.</given-names></name><name><surname>Shih</surname><given-names>C.</given-names></name><name><surname>Corey</surname><given-names>E.J.</given-names></name><name><surname>Lewis</surname><given-names>R.A.</given-names></name><name><surname>Austen</surname><given-names>K.F.</given-names></name></person-group><article-title>Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product</article-title><source>J. Biol. Chem.</source><volume>259</volume><year>1984</year><fpage>2383</fpage><lpage>2389</lpage><pub-id pub-id-type="pmid">6321468</pub-id></citation></ref><ref id="R25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Wong</surname><given-names>P.Y.</given-names></name><name><surname>Samuelsson</surname><given-names>B.</given-names></name></person-group><article-title>Nomenclature of lipoxins and related compounds derived from arachidonic acid and eicosapentaenoic acid</article-title><source>Prostaglandins.</source><volume>34</volume><year>1987</year><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">2823318</pub-id></citation></ref><ref id="R26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>D.J.</given-names></name><name><surname>Griffiths</surname><given-names>D.H.</given-names></name><name><surname>Rowley</surname><given-names>A.F.</given-names></name></person-group><article-title>Trout thrombocytes contain 12- but not 5-lipoxygenase activity</article-title><source>Biochim. Biophys. Acta.</source><volume>1437</volume><year>1999</year><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9931438</pub-id></citation></ref><ref id="R27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname><given-names>B.N.</given-names></name><name><surname>Kimmel</surname><given-names>S.C.</given-names></name><name><surname>Levin</surname><given-names>R.I.</given-names></name><name><surname>Martiniuk</surname><given-names>F.</given-names></name><name><surname>Weissmann</surname><given-names>G.</given-names></name></person-group><article-title>A mechanism for the antiinflammatory effects of corticosteroidsthe glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1</article-title><source>Proc. Natl. Acad. Sci. USA.</source><volume>89</volume><year>1992</year><fpage>9991</fpage><lpage>9995</lpage><pub-id pub-id-type="pmid">1279685</pub-id></citation></ref><ref id="R28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokomizo</surname><given-names>T.</given-names></name><name><surname>Izumi</surname><given-names>T.</given-names></name><name><surname>Chang</surname><given-names>K.</given-names></name><name><surname>Takuwa</surname><given-names>T.</given-names></name><name><surname>Shimizu</surname><given-names>T.</given-names></name></person-group><article-title>A G-protein-coupled receptor for leukotriene B<sub>4</sub> that mediates chemotaxis</article-title><source>Nature.</source><volume>387</volume><year>1997</year><fpage>620</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">9177352</pub-id></citation></ref><ref id="R29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>M.R.</given-names></name><name><surname>Horsewood</surname><given-names>P.</given-names></name><name><surname>Brister</surname><given-names>S.J.</given-names></name></person-group><article-title>Regulation of endothelial cell and platelet receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides, 12-, 15-HETE and 13-HODE</article-title><source>Prostaglandins Leukot. Essent. Fatty Acids.</source><volume>58</volume><year>1998</year><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">9690711</pub-id></citation></ref><ref id="R30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P.M.</given-names></name><name><surname>Cushman</surname><given-names>M.</given-names></name><name><surname>Stampfer</surname><given-names>M.J.</given-names></name><name><surname>Tracy</surname><given-names>R.P.</given-names></name><name><surname>Hennekens</surname><given-names>C.H.</given-names></name></person-group><article-title>Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men</article-title><source>N. Engl. J. Med.</source><volume>336</volume><year>1997</year><fpage>973</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">9077376</pub-id></citation></ref></ref-list><fn-group><fn><p>Presented in part at the 11th International Conference on Advances in Prostaglandin and Leukotriene Research, plenary session June 5, 2000, Florence, Italy.</p></fn></fn-group></back><floats-wrap><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Hydroxy Compounds Generated from PUFA and Recombinant Human COX-2 with ASA or a Selective COX-2 Inhibitor</p></caption><table frame="hsides" rules="groups"><thead><tr valign="bottom" align="center"><th/><th/><th colspan="3" rowspan="1">Hydroxy-containing compounds (ng/incubation)</th></tr><tr valign="bottom"><th align="left">PUFA</th><th align="center">NSAID</th><th align="center">&#x003c9;-2</th><th align="center">&#x003c9;-5</th><th align="center">&#x003c9;-9</th></tr></thead><tbody><tr valign="bottom"><td align="center"/><td align="center"/><td align="center"/><td align="char" char=".">13-HODE</td><td align="char" char=".">9-HODE</td></tr><tr valign="bottom"><td align="center">C18:2</td><td align="center">ASA</td><td align="center">&#x02013;</td><td align="char" char=".">2.9 &#x000b1; 0.6</td><td align="char" char=".">25.2 &#x000b1; 17.8</td></tr><tr valign="bottom"><td align="center">C18:2</td><td align="center">Vehicle alone</td><td align="center">&#x02013;</td><td align="char" char=".">55.0 &#x000b1; 18.7</td><td align="char" char=".">243.0 &#x000b1; 68.6</td></tr><tr valign="bottom"><td align="center"/><td align="center"/><td align="center"/><td align="char" char=".">15<italic>R</italic>-HETE</td><td align="char" char=".">11<italic>R-</italic>HETE</td></tr><tr valign="bottom"><td align="center">C20:4</td><td align="center">ASA</td><td align="center">&#x02013;</td><td align="char" char=".">234.0 &#x000b1; 112.5</td><td align="char" char=".">1.4 &#x000b1; 1.6</td></tr><tr valign="bottom"><td align="center">C20:4</td><td align="center">Vehicle alone</td><td align="center">&#x02013;</td><td align="char" char=".">11.5 &#x000b1; 8.2</td><td align="char" char=".">1.8 &#x000b1; 1.0</td></tr><tr valign="bottom"><td align="center">C20:4</td><td align="center">Selective inhibitor</td><td align="center">&#x02013;</td><td align="char" char=".">5.5 &#x000b1; 0.8</td><td align="char" char=".">0.9 &#x000b1; 0.1</td></tr><tr valign="bottom"><td align="center"/><td align="center"/><td align="char" char=".">18<italic>R</italic>-HEPE</td><td align="char" char=".">15<italic>R</italic>-HEPE</td><td align="char" char=".">11<italic>R-</italic>HEPE</td></tr><tr valign="bottom"><td align="center">C20:5</td><td align="center">ASA</td><td align="char" char=".">16.2 &#x000b1; 3.3</td><td align="char" char=".">16.8 &#x000b1; 5.8</td><td align="char" char=".">5.4 &#x000b1; 3.3</td></tr><tr valign="bottom"><td align="center">C20:5</td><td align="center">Vehicle alone</td><td align="char" char=".">7.0 &#x000b1; 3.3</td><td align="char" char=".">17.9 &#x000b1; 5.2</td><td align="char" char=".">40.7 &#x000b1; 10.3</td></tr><tr valign="bottom"><td align="center">C20:5</td><td align="center">Selective inhibitor</td><td align="char" char=".">5.8 &#x000b1; 2.6</td><td align="char" char=".">0.0 &#x000b1; 0.6</td><td align="char" char=".">0.0 &#x000b1; 0.3</td></tr></tbody></table><table-wrap-foot><fn><p>Results are the mean &#x000b1; SEM, <italic>n</italic> = 3. The selective COX-2 inhibitor NS398 was used at 100 &#x003bc;M. All products were extracted, identified, and quantitated using internal standards and LC/MS/MS. Compounds of interest are shown in bold type.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p>Inflammatory exudates from murine dorsal pouches treated with aspirin generate novel compounds: LC/MS/MS. TNF-&#x003b1;&#x02013;induced leukocyte exudates collected at 6 h from FVB mice given ASA (3.5 h at 500 &#x003bc;g/air pouch) and EPA (4 h at 300 &#x003bc;g/pouch) contained (2.3 &#x000b1; 0.5 &#x000d7; 10<sup>6</sup> leukocytes per pouch)&#x0003b; see Materials and Methods. (A) Selected ion chromatogram of mono-HEPEs. (B) MS/MS of 18<italic>R</italic>-HEPE. (C) MS/MS of 5<italic>S</italic>-HEPE. (D) MS/MS of 12,15,18<italic>R</italic>-triHEPE (see text for identification of diagnostic ions). Results are representative of <italic>n</italic> = 4.</p></caption><graphic xlink:href="JEM000832.f1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Human ECs and PMNs: novel trihydroxy-containing compounds LC/MS/MS. (A) HUVECs treated with IL-1&#x003b2; (24 h) and ASA. (B) Human PMNs (&#x0223c; 30 &#x000d7; 10<sup>6</sup>/ml) incubated (30 min, 37&#x000b0;C) with serum-treated zymosan (100 ng/ml) and acetylated ASA-recombinant COX-2&#x02013;derived products from EPA. (C) MS/MS of 5,12,18<italic>R</italic>-triHEPE (see text for ions and fragmentation). (D) MS/MS of 15-epi-LXA<sub>5</sub>. Results are representative of <italic>n</italic> = 3&#x02013;5 for PMNs and <italic>n</italic> = 3 for ECs.</p></caption><graphic xlink:href="JEM000832.f2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>The novel compounds inhibit human PMN transmigration and inflammation in the murine air pouch. (A) Inhibition of PMN transendothelial migration. PMNs were incubated with isolated compounds [10<sup>&#x02212;10</sup>&#x02013;10<sup>&#x02212;6</sup> M] 18<italic>R</italic>-HEPE (&#x025cb;), 5,12,18<italic>R</italic>-triHEPE (&#x02022;), or ATL analogue used for reference (&#x02666;), and transmigration was initiated using an optimal amount of LTB<sub>4</sub> [10 nM] (100%) and HUVEC coincubations (90 min, 37&#x000b0;C). Results are the mean &#x000b1; SEM&#x0003b; <italic>n</italic> = 3. (B) Competition binding with human recombinant LTB<sub>4</sub> receptor. LTB<sub>4</sub> receptor stably expressed in HEK293 cells (&#x0223c;5 &#x000d7; 10<sup>5</sup> cells/incubation) were incubated with [<sup>3</sup>H]LTB<sub>4</sub> (&#x0223c;1 nM) plus LTB<sub>4</sub> (&#x025aa;) and 18<italic>R</italic>-HEPE (&#x025cb;), 5,12,18<italic>R</italic>-triHEPE (&#x02022;), or LTB<sub>5</sub> (&#x025a1;). Results are the mean &#x000b1; SEM from <italic>n</italic> = 3. (C) Inhibition of leukocyte trafficking in 6 d dorsal air pouch. TNF-&#x003b1; (100 ng) was injected intrapouch and 100 ng i.v. tail vein of test compound. ATLa (analogue 15(<italic>S</italic>)-16(parafluoro)-phenoxy-LXA<sub>4</sub>&#x0003b; reference 16) was used for comparison. Results represent <italic>n</italic> = 4.</p></caption><graphic xlink:href="JEM000832.f3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Proposed scheme for generating functional arrays of lipid signals from &#x003c9;-3 PUFA via transcellular processing: endogenous inhibitors of microinflammation. At sites where COX-2 is upregulated and treated with NSAIDs, PG formation from C20:4 is blocked. Systemic &#x003c9;-3 PUFAs are converted via a COX-2&#x02013;NSAID lipoxygenase&#x02013;type mechanism that abstracts hydrogen in a stereospecific fashion at C16 or C13 in C20:5 to give <italic>R</italic> insertions of molecular O<sub>2</sub> to yield 15<italic>R</italic>-H(p)EPE or 18<italic>R</italic>-H(p)EPE to form epoxides or are reduced to alcohols. The complete stereochemistry for each of the trihydroxy compounds remains to be determined, and the compounds are depicted in their likely configurations. These compounds interact with cells in the local microenvironment, inhibiting PMN recruitment. COX-2&#x02013;NSAID-dependent hydrogen abstraction and insertion of molecular oxygen occurs with all &#x003c9;-3 PUFAs containing 1,4-cis pentadiene units tested (see text for details). Thus, sequential oxygenations of &#x003c9;-3 PUFA during cell&#x02013;cell interactions generate novel arrays of signals of interest in microinflammation.</p></caption><graphic xlink:href="JEM000832.f4"/></fig></floats-wrap></article>


